Overview
Goals and Objectives
Our Team
Publications
Collaborations
Lines of Research
Awards
Projects
Overview
Goals and Objectives
Our broader aim is to investigate the molecular perturbations involved in CVDs such as hypertension, vascular dysfunction, atherosclerosis, thrombosis, and ischemia- and hypertension-induced cardiac remodeling and heart failure. Moreover, considering several structural and functional similarities between cardiac and skeletal muscles, the CVR group is also focusing on investigating the potential molecular mechanisms responsible for the coupling of cardiac and skeletal muscle dysfunction. We will pursue these aims through the following specific objectives:
- Identify genes and genetic defects and delineate the underlying molecular mechanisms to enhance our understanding of CVDs, including various types of cardiomyopathies, thrombotic and vascular disorders, endothelial dysfunction, familial hypercholesterolemia, and inherited bleeding disorders.
- Perform detailed phenotypic and molecular characterization of patients with major CVDs.
- Establish potential circulating biomarkers for the early risk assessment and treatment of CVDs.
- Identify and characterize novel drug targets using in vitro and in vivo mouse models.
- Delineate the molecular mechanisms causing the coupling of cardiac and skeletal muscle dysfunction and evaluate the effects of microgravity on cardiovascular remodeling.
- Screen small-molecule inhibitors to develop improved therapeutic strategies for CVDs.
- Investigate immunopharmacological interventions related to renal and cardiovascular disorders.
Research Publications
No Record Found
Collaborations
- Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
- College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia
- Faculty of Medicine, Department of Cardiology, Mansoura University, Egypt
- Niigata University Graduate School of Medical and Dental Sciences, Japan
- Mohammed Bin Rashid University, Dubai, UAE
- Simon Fraser University, Canada
List of institutions and organizations collaborating with us to achieve our research and community goal:
Line of Research
The Cardiovascular Research Group employs an integrated, multi-disciplinary approach that combines in vitro, ex vivo, and in vivo models to address fundamental and translational questions in cardiovascular and skeletal muscle biology. Using advanced gain- and loss-of-function strategies, we investigate the molecular, cellular, and genetic mechanisms underlying cardiovascular and neuromuscular disorders. Our primary research interests include ischemic heart disease, pressure overload-induced cardiac remodeling and heart failure, hypertension, vascular dysfunction, thrombosis, atherosclerosis, inflammation, and metabolic dysregulation.
In addition, our group explores the effects of microgravity, prolonged bed rest, and physical inactivity on cardiovascular and skeletal muscle health using spaceflight-relevant animal models. We are particularly interested in understanding the mechanisms driving muscle atrophy, functional decline, and associated cardiovascular complications under these conditions.
The group maintains well-established cardiac, vascular, and skeletal muscle cell culture systems, together with state-of-the-art molecular, genetic, and biochemical platforms, to dissect disease mechanisms and identify novel therapeutic targets. Our research also focuses on the discovery and evaluation of small-molecule modulators and other innovative therapeutic strategies using in vitro, ex vivo, and preclinical models, with the ultimate goal of preventing, attenuating, or reversing cardiovascular diseases.
Awards
Below are the awards and recognitions received by our members, reflecting their excellence and academic achievements:
- American Heart Association (AHA), Paul Dudley White International Scholar Award, in the Basic Cardiovascular Sciences Scientific Sessions 2024 to Dr. Adel Elmoselhi

